Receive E-mail Alerts

Subscribe to RSS feeds

Keyword Search

2009 | 2008 | 2007 | 2006 | 2005 | 2004

Date	Title
12/15/2008	SDI and MedImmune Publish Ground-Breaking Study on Geographically Specific, Seasonal RSV Disease Outbreak Data
12/4/2008	MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
11/28/2008	MedImmune Receives FDA Complete Response Letter on Motavizumab
11/17/2008	MedImmune Announces Winners of Third Annual Research Abstract Competition
11/13/2008	MedImmune Announces Zook as President
11/3/2008	MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
10/24/2008	MedImmune to Present Nine Abstracts on RSV and Influenza at 48th Annual ICAAC/46th Annual IDSA Meeting
10/23/2008	MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
10/16/2008	MedImmune Licenses Reverse Genetics Technology to Hungary's Omninvest for Use in Influenza Vaccine Development and Production
10/16/2008	MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
10/13/2008	MedImmune Grants Five New Fellowships to Help Expand Premature Infant Follow-Up Care Research
10/11/2008	MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
9/29/2008	MedImmune Licenses Reverse Genetics Technology to Japan's BIKEN for Use in Influenza Vaccine Development and Production
9/11/2008	MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
8/21/2008	Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu
8/12/2008	MedImmune Initiates First Phase 2 Trial in Lupus Patients With its Antibody Targeting Interferon-alpha
8/4/2008	FluMist(R) Now Available for the 2008-2009 Flu Season
6/12/2008	Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
6/6/2008	MedImmune's Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
5/15/2008	Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
5/6/2008	MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
5/5/2008	Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors' Visits
5/5/2008	Efficacy of FluMist(R) in Children Highlighted at Pediatric Academic Societies Meeting
5/5/2008	Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
5/4/2008	Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
4/28/2008	Fourteen Abstracts Featuring MedImmune's Influenza and RSV Therapeutic Areas to Be Presented at Pediatric Academic Societies Annual Meeting
4/15/2008	MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
4/15/2008	Preclinical Data Highlighting Potential of Retaspimycin in Treating Non-Small Cell Lung Cancer With Acquired Drug Resistance Presented by Infinity and MedImmune At AACR
4/10/2008	MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
3/27/2008	Seneca Valley High School Student Receives Science Award From MedImmune
3/18/2008	MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
2/27/2008	MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
2/19/2008	Neonatologists and Pediatricians Highlight Progress and Barriers to Preemie Care
2/7/2008	MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
2/4/2008	MedImmune Submits Biologics License Application to FDA for Motavizumab
2/4/2008	Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor
1/7/2008	MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
1/4/2008	Infinity and MedImmune Initiate Phase 1b Trial of IPI-504 in Combination with TaxotereŽ in Patients with Advanced Solid Tumor Cancers